GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Debt-to-Equity

Paion Ag (Paion Ag) Debt-to-Equity : -6.93 (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Debt-to-Equity?

Paion Ag's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $3.00 Mil. Paion Ag's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $20.02 Mil. Paion Ag's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-3.32 Mil. Paion Ag's debt to equity for the quarter that ended in Jun. 2023 was -6.93.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Paion Ag's Debt-to-Equity or its related term are showing as below:

PAIOF' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.93   Med: 0.3   Max: 3.08
Current: -6.93

During the past 13 years, the highest Debt-to-Equity Ratio of Paion Ag was 3.08. The lowest was -6.93. And the median was 0.30.

PAIOF's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs PAIOF: -6.93

Paion Ag Debt-to-Equity Historical Data

The historical data trend for Paion Ag's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Debt-to-Equity Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.30 - 2.89 3.08

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 2.89 1.21 3.08 -6.93

Competitive Comparison of Paion Ag's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paion Ag's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion Ag's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Paion Ag's Debt-to-Equity falls into.


Paion Ag Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Paion Ag's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.517 + 20.042) / 7.007
=3.08

Paion Ag's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.004 + 20.018) / -3.322
=-6.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion Ag  (OTCPK:PAIOF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Paion Ag Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Paion Ag's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Paion Ag (Paion Ag) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Debt-to-Equity
Comparable Companies
FRA:SPB HAM:GWK3 STU:DWB FRA:BBI HAM:TLG ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124 BOM:532321
Traded in Other Exchanges
PA8:Germany
Address
Heussstrasse 25, Aachen, DEU, 52078
Website
https://www.paion.com
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.